We've changed the way you complete courses

In response to user feedback we have simplified the way courses can be completed.

Until now you needed to complete the topics and modules in order, from start to finish. But from today you can complete them in any order you wish.

Just visit any topic that interests you, and when you are ready mark it as completed by clicking the green 'Mark complete' button at the bottom of the page.

Once you have completed all of the topics in a module an assessment will be provided for you.

Complete all the assessments to finish the course.

Thanks, I've got it! X

Of interest, we also looked in a post-hoc analysis at the effects of liraglutide in those people who still had C-peptide on board and, thus, had functioning beta cells on board. It was obvious that the effect was nicer on HbA1c when looking at those who still had C-peptide. Also the risk of ketosis and the risk of hypoglycaemia was less in those who still had C-peptide on board and, thus, functioning beta cells on board.
Play the audio to learn more about the effect of liraglutide on patients with functioning beta cells
Summary of symptomatic hypoglycaemia by baseline C-peptide (<LLOQ and ≥LLOQ – week 52 – full analysis set:
Select image for larger view

Summary of on-treatment data. This summary includes treatment-emergent episodes with onset dates on or after the first day on treatment and no later than the day after the last day on treatment. Symptomatic hypoglycaemic episodes are episodes that, according to Novo Nordisk definition, are either severe according to the ADA definition or are accompanied by a plasma glucose value of <3.1 mmol/L (56 mg/dL), with symptoms consistent with hypoglycaemia.

ADA: American Diabetes Association
E: number of events (episodes)
FAS: full analysis set
LLOQ: lower limit of quantification (0.03 nmol/L)
N: number of subjects with at least one even (episode)
R: event rate per subject year of exposure
%: percentage of subjects with at least one event (episode)

Summary of hyperglycaemia with ketosis by baseline C-peptide (<LLOQ or ≥LLOQ):
Select image for larger view

LLOQ: lower limit of quantification for baseline C-peptide
On-treatment analysis. Exposure refers to the cumulative time in trial.

Mathieu C, Zinman B, Hemmingsson JU, Woo V, Colman P, Christiansen E, Linder M, Bode B; ADJUNCT ONE Investigators. Efficacy and Safety of Liraglutide Added to Insulin Treatment in Type 1 Diabetes: The ADJUNCT ONE Treat-To-Target Randomized Trial. Diabetes Care. 2016 Oct;39(10):1702-10